Abstract Bone is the most common site of metastasis of breast cancer, affecting most women with advanced disease. Procollagen type I N-terminal propeptide (P1NP), osteocalcin, CTX, and IL-6 are markers of bone turnover. Our objective was to determine whether serum levels of these proteins have clinical utility as predictors of breast cancer metastasis to bone. Blood was collected before treatment from 164 patients with stage I-III breast cancer from September 2001 to December 2008. Serum levels of P1NP, CTX, IL-6, and OC were measured using an automated immunoassay system. Correlations of the levels of these markers with time to bone metastasis development and with overall survival (OS) rate were assessed using Cox proportional hazards regression analysis and the KaplanMeier method. Fifty-five patients with stage I-III disease at the time of blood sample collection subsequently experienced metastasis to bone. A baseline P1NP level of at least 75 ng/mL predicted increased risk of bone metastasis (hazard ratio, 2.7 [95 % confidence interval, 1.2-6.0]; P = 0.031) and a poor OS rate (P = 0.031). Serum P1NP levels at or above 75 ng/mL correlate with a short time to development of bone metastasis and low overall survival in patients with stage I-III breast cancer.
Introduction
Breast cancer accounts for almost 25 % of all new cancer cases diagnosed in the United States each year [1] . Bone is the most common site of breast cancer metastases, affecting more than 50 % of women with advanced disease [2, 3] . Although therapies for bone metastases of breast cancer are available, patients still experience significant morbidity and mortality, with a median life expectancy of 4 years after diagnosis [4] .
As with other bone-related diseases, development of bone metastasis of breast cancer is a multistep process-dependent on a balance between bone resorption and bone formation. In general, this process consists of detachment of tumors cells from the primary tumor, migration, and attachment of tumor cells to the bone marrow, cellular invasion of the bone matrix, and interactions between the tumor and bone matrix cells (e.g., seed and soil theory) with resultant development of osteolytic lesions [5] . Researchers have proposed that development of bone metastasis in breast cancer patients is driven by proteins released by tumor cells and the bone microenvironment that serve as ''homing markers,'' directing tumor cells to bone.
Over the past 20 years, researchers have identified more than a dozen proteins that may be considered biomarkers of bone metastasis in preclinical models of breast cancer and in human breast tumors (Table 1 ) [6] [7] [8] [9] [10] [11] [12] . Some of these biomarkers appear to be useful for monitoring bone metabolism in patients with various bone-related diseases, including osteoporosis, as well as monitoring patients receiving antiresorptive agents [13, 14] . However, biomarkers for the identification of patients at increased risk for bone metastasis of breast cancer have yet to be validated and implemented clinically. Furthermore, as understanding of the biological processes involved in metastasis of breast cancer to bone evolves and targeted treatments of bone metastases enter the clinic, identification of markers that assist in assessing therapeutic response to these agents will be needed [15] [16] [17] [18] [19] .
The identification of clinically useful predictive markers of bone metastasis in patients with early-stage breast cancer will allow us to design appropriate interventions to interfere with the metastatic process in this population. The aim of this study was to determine the association of serum levels of the biomarker procollagen type I N-terminal propeptide (P1NP) with the development of bone metastasis in patients with early stage breast cancer. Our hypothesis was that elevated levels of circulating P1NP would correlate with an increased risk of bone metastasis. Discovering circulating biomarkers associated with the development of metastatic breast cancer to bone is critical to identifying patients for whom early intervention could decrease the risk of this potentially fatal complication.
Patients and methods

Patients
Blood samples were collected from 164 patients with stage I-III breast cancer seen at The University of Texas MD Anderson Cancer Center from September 2001 to December 2008. All patients were staged with chest X-ray, bone scan, and CT of the abdomen to rule out distant metastasis at the time of diagnosis. Table 2 shows the characteristics of the patients included in this study. The samples were collected before definitive surgery or neoadjuvant chemotherapy and banked for future use. Sample collection, banking and analyses were conducted according to protocols approved by an Institutional Review Board.
Blood samples
The blood samples were collected from the patients in evacuated Monovette plastic tubes (Sarstedt, Newton, NC) and centrifuged at 2,0009g for 15 min at room temperature within 2 h after venipuncture. Samples were taken in the morning, but fasting was not required. The samples were then aliquoted and stored at -80°C.
Measurement of biomarker levels in serum
Serum levels of P1NP, CTX, IL-6, and OC were measured using an Elecsys 2010 automated immunoassay system (Roche, Indianapolis, IN). This electrochemiluminescent method uses streptavidin-labeled microparticles and monoclonal antibodies labeled with a ruthenium complex. Following validation of accuracy, precision, linearity, and limits of detection, the assay was used to simultaneously measure the levels of the selected analytes in serum samples. The samples were shuffled before testing, and the level of each biomarker was measured in duplicate (average of duplicates was used for analysis). Laboratory personnel were blinded to the patients' identities and clinical data. Time to metastasis was measured from the date of blood sample to the date of discovery of metastasis or last follow-up visit. Overall survival (OS) was measured from the date of blood sample to date of death or last contact. [20] .
Results
Correlation of P1NP with osteocalcin and CTX
Both osteocalcin and CTX were significantly (P \ 0.0001) correlated with P1NP based on Spearman's rank correlation coefficients (osteocalcin: q = 0.72, CTX: q = 0.53).
Association of serum biomarkers levels with time to development of bone metastasis
Of the 164 study patients, 55 had bone metastases. Of note is that for 21 of the 107 patients without bone metastases, the follow-up duration was under 2 years. As a result, we were not able to treat bone metastasis development as a binary endpoint and thus could not directly compare patients with and without bone metastases.
Residual analysis suggested the existence of nonlinear relationships between each biomarker and risk of developing bone metastasis during follow-up. Thus, we fit Cox proportional hazards regression models for each biomarker with quadratic polynomials (on the log scale). Univariate analysis revealed no associations of risk of subsequent development of bone metastasis with serum levels of IL-6, OC, CTX, or P1NP (P = 0.18, 0.31, 0.37, and 0.20, respectively). However, adjusting the analysis for clinical factors (disease stage, age, race, post-menopause, estrogen receptor/progesterone receptor status, HER2 status, nuclear grade) yielded statistical significance for the quadratic polynomial for log P1NP (P = 0.043). The endpoint is bone recurrence at any time after baseline sample was obtained.
The serum levels of P1NP ranged from 12.8 to 212.0 ng/ mL, with a median level of 44.3 ng/mL. Only four of the patients' levels were greater than 100 ng/mL. A cut point of 75 ng/mL identified patients with short times to development of bone metastasis (hazard ratio (HR), 2.7 [95 % confidence interval (CI), 1.2-6.0]; P = 0.031) (Fig. 1a) .
The cut-off of 75 was selected as the best choice after investigation of several potential cut offs. Since it was selected from among a set of candidates, we cannot be sure of the true significance of this cut-off value. It would need to be validated in an independent dataset. The 1-, 2-, 3-, and 4-year freedom-from-bone-metastasis probabilities were 100, 89, 79, and 73 %, respectively, in patients with P1NP levels less than 75 ng/mL and 98, 61, 51, and 41 % in patients with P1NP levels at or greater than 75 ng/mL. After adjustment for clinical factors, the HR was 2.9 (95 % CI, 1.2-7.2; P = 0.019).
Correlation between the bone biomarkers and first relapse There were 80 distant metastasis events (time to first distant metastasis), Kaplan-Meier freedom-from-distant mets: 2 years = 73 %, 4 years = 55 %, 6 years = 48 %. Cox PH models with biomarkers analyzed as continuous variables on the log scale showed none of the four markers were predictive. There were 82 local/regional/distant metastasis events (time to first recurrence), Kaplan-Meier freedom from recurrence: 2 years = 73 %, 4 years = 54 %, 6 years = 47 %. In only 2 out of 164 patients is the time to first distant met much different from the time to first recurrence of any type, suggesting that the results for time to first recurrence will not be much different from those for time to first distant metastasis.
Association of serum biomarker level with survival rate
Univariate analysis demonstrated that serum levels of P1NP, IL-6, OC, and CTX at diagnosis of breast cancer did not significantly correlate with OS. However, after adjustment for clinical factors, multivariate Cox proportional hazards regression analysis showed that the OC level was an independent predictor of OS (P = 0.04).
When modeled as a quadratic polynomial on the log scale, the serum P1NP level was associated with OS (P = 0.022) even after adjustment for clinical factors (P = 0.0056). When dichotomized at 75 ng/mL, high levels of P1NP were associated with poor survival (HR, 2.4 [95 % CI, 1.2-4.7]; P = 0.031) even after adjustment for clinical factors (HR, 3.3 [95 % CI, 1.5-7.3]; P = 0.0036) (Fig. 1b) .
Discussion
We evaluated several proteins in serum as potential biomarkers for identifying women with early-stage breast cancer who are at increased risk for bone metastasis. This study is unique that in addition to evaluating some of the standard proteins that investigators have used to assess bone homeostasis (OC and CTX), we also evaluated two other proteins shown to have roles in signaling pathways involved in the development of bone metastasis (P1NP and IL-6) [21] [22] [23] . We found that a serum P1NP level of at least 75 ng/mL at the time of breast cancer diagnosis correlated with a short time to development of bone metastasis and short overall survival rate in patients with stage I-III breast cancer.
A few studies have demonstrated associations between elevated P1NP levels and development of certain cancers, particularly those with a high prevalence of metastasis to bone, such as breast and prostate cancer [22] [23] [24] . Furthermore, researchers have shown that P1NP is a potential predictor of bone metastasis and of disease progression and survival in patients with prostate cancer [23] . More recent studies have examined the use of the serum P1NP level as a tool for estimating the extent of bone involvement and detecting bone metastases in patients with breast cancer [25] [26] [27] .
Studies have demonstrated elevated serum concentrations of P1NP in up to 70 % of patients with breast cancer having confirmed bone metastases [26] [27] [28] . In a randomized trial, patients with estrogen receptor-positive metastatic breast cancer treated with exemestane plus everolimus had higher P1NP levels than did patients who received exemestane alone, suggesting that P1NP is a predictive biomarker for bone metastasis in this population [29] . McCloskey et al. evaluated the predictive role of P1NP in patients treated with clodronate in the adjuvant setting. In this study, patients who received clodronate had a median 26 % reduction in levels of serum P1NP after 2 years of therapy, compared with a median 5 % increase in patients who received placebo (P \ 0.0001). Early changes in PINP were associated with changes in bone mineral density and the likelihood of developing bone metastases [30] . However, to our knowledge, this is the first study to demonstrate that baseline levels of P1NP can be used to identify women with early-stage breast cancer at increased risk for bone metastasis. This is highly significant in light of the fact that bone metastasis is a major contributor to the morbidity and mortality of breast cancer [31] [32] [33] [34] . In addition, preliminary data demonstrating that use of bisphosphonates and the RANK ligand (RANKL) inhibitor denosumab is able to decrease the time to development of the first and subsequent skeletal-related events (e.g., pathological fractures, spinal compression, radiation or surgery to bone or tumor-induced hypocalcaemia) supports a potential role for these agents in adjuvant treatment of breast cancer [15] [16] [17] [18] [35] [36] [37] [38] [39] . However, what patients are likely to benefit from this type of intervention is not known [40] .
The correlation of elevated serum levels of OC at diagnosis of breast cancer and poor prognosis in the present study is in line with the results of previously published reports [41, 42] thus, we used it as a reference protein for bone homeostasis in the present study. However, the lack of prognostic value for serum levels of CTX are somewhat surprising. CTX is a marker of bone resorption, and elevated serum levels have been documented in patients with prostate or breast cancer having bone metastasis [43] [44] [45] . CTX levels are usually measured in urine samples, and measurement of this biomarker in blood samples obtained from breast cancer patients as performed in our study is fairly unique and may account for the discrepancy regarding prognosis.
Researchers have also evaluated the role of IL-6 in prognosis for bone metastasis, finding that elevated serum levels of IL-6 and soluble IL-6 receptor were associated with poor clinical outcome in patients with metastatic breast cancer [21, 46, 47] . IL-6, which is produced in the bone marrow microenvironment, also can enhance bone degradation in several ways, including stimulation of RANKL production by osteoblasts [48, 49] . Thus, the correlation we observed between serum IL-6 level and DFS rate (P = 0.056) is not surprising. Evaluation of IL-6 levels has offered the unique opportunity to identify effective targeted agents for treatment of breast cancer, as monoclonal antibodies and small molecule inhibitors of IL-6-mediated signaling molecules are now undergoing testing in phase 1 and 2 clinical trials [21] .
New clinical trial designs are needed to prevent development of bone metastasis in patients at high risk [50] . Our study was limited by the small sample size, which was determined by the available samples in our serum bank at the time we performed the study. We had baseline samples for all patients but follow-up samples for only a subset of them. Serial measurement of the four markers tested in serum likely will be more informative than single biomarkers, although this hypothesis must be tested prospectively. This study is retrospective and therefore hypothesisgenerating. If our observations are confirmed by larger studies, a randomized clinical trial would be justified for women with serum P1NP levels of at least 75 ng/mL at the time of breast cancer diagnosis to determine whether adjuvant bisphosphonates or denosumab improves DFS and OS rates.
Translational relevance
Bone is the most common site of metastasis in patients with advanced breast cancer. Development of bone metastasis is associated with high mortality and morbidity. There are currently no biomarkers to identify patients with early-stage breast cancer who are likely to develop metastatic disease to the bone. We measured serum levels of bone turnover markers, including procollagen type I N-terminal propeptide (P1NP), osteocalcin, CTX, and IL-6 in patients with clinical stage I-III breast cancer, before initiation of definitive treatment. Serum procollagen type I N-terminal propeptide (P1NP) levels of at least 75 ng/mL at the time of breast cancer diagnosis correlated with an shorter time to development of bone metastasis and shorter overall survival rate in patients with stage I-III disease. Serum P1NP levels may be used for patient selection in future clinical trials of agents designed to prevent bone metastasis.
